<?xml version="1.0" encoding="UTF-8"?>
<xml>
  <records>
    <record>
      <source-app name="Horizon">Horizon</source-app>
      <rec-number>1</rec-number>
      <foreign-keys>
        <key app="Horizon" db-id="fdi:010066573">1</key>
      </foreign-keys>
      <ref-type name="Journal Article">17</ref-type>
      <work-type>ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES</work-type>
      <contributors>
        <authors>
          <author>
            <style face="normal" font="default" size="100%">Camlin, C.S.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Seeley, J.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Viljoen, L.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Vernooij, E.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Simwinga, M.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Reynolds, L.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Reis, R.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Plank, R.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Orne-Gliemann, J.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">McGrath, N.</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Larmarange, Joseph</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Hoddinott, G.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Getahun, M.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Charlebois, E.D.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Bond, V.</style>
          </author>
        </authors>
      </contributors>
      <titles>
        <title>Strengthening universal HIV 'test-and-treat' approaches with social science research</title>
        <secondary-title>AIDS</secondary-title>
      </titles>
      <pages>969-970</pages>
      <keywords>
        <keyword>AFRIQUE</keyword>
      </keywords>
      <dates>
        <year>2016</year>
      </dates>
      <call-num>fdi:010066573</call-num>
      <language>ENG</language>
      <periodical>
        <full-title>AIDS</full-title>
      </periodical>
      <isbn>0269-9370</isbn>
      <accession-num>ISI:000371905500019</accession-num>
      <number>6</number>
      <electronic-resource-num>10.1097/QAD.0000000000001008</electronic-resource-num>
      <urls>
        <related-urls>
          <url>https://www.documentation.ird.fr/hor/fdi:010066573</url>
        </related-urls>
        <pdf-urls>
          <url>https://horizon.documentation.ird.fr/exl-doc/pleins_textes/divers16-03/010066573.pdf</url>
        </pdf-urls>
      </urls>
      <volume>30</volume>
      <remote-database-provider>Horizon (IRD)</remote-database-provider>
      <abstract>Strengthening universal HIV 'test-and-treat' approaches with social science research The recent publication of new WHO guidelines, including a call for antiretroviral therapy for everyone diagnosed with HIV regardless of CD4 þ cell count and preexposure prophylaxis for people at substantial risk of HIV infection [1], marks an important moment for taking stock of what will be needed to take biomedical HIV prevention approaches to scale, and sustain them. As the author of a recent editorial in The Lancet [2] observes, these guidelines are 'welcome but ambitious. [.. .] No studies exist that address how such a strategy can be executed on a global scale' (p. 1420). We, a multidisciplinary group of social scientists working as part of five large-scale 'universal test-and-treat' (UTT) trials being implemented across six African countries, would argue that successful large-scale expansion of treatment and preexposure prophylaxis will require an indepth understanding of the heterogeneous community and health systems' contexts of the rollout.</abstract>
      <custom6>056</custom6>
      <custom1>UR196</custom1>
      <custom7>Afrique du Sud / Zambie</custom7>
    </record>
  </records>
</xml>
